Rapid Unit Sales Of Oncology Molecular Diagnostic Market To Generate Incremental Revenues In Global Market : Fact.MR

Rockville, United States , 2022-May- 24 — /EPR Network/ —As per Fact.MR, a market research and competitive intelligence provider, the global oncology molecular diagnostic market is predicted to expand at a CAGR of 11% over the forecast period (2021–2031).

Oncology molecular diagnosis is a method used to identify cancer at the molecular level using proteins, DNA, and RNA, in a tissue or fluid. Various tools are used to detect specific sequences of DNA or RNA that may be associated with the disease, such as single nucleotide polymorphism (SNP), deletions, rearrangements, and insertions.

Factors such as increase in prevalence of various types of cancers, rise in awareness and acceptance of personalized medicines, and growth in biomarker identification are driving market growth.

For critical insights on this market, request for More Info –  https://www.factmr.com/connectus/sample?flag=S&rep_id=6864

Key Takeaways from Market Study

• Global oncology molecular diagnostic market is expected to grow 2.3X in value by 2031.
• Demand for reagents & kits to expand at a CAGR of 12.8% over next ten years.
• Market in China anticipated to reach a valuation of US$ 670 Mn by 2031.
• Markets in Japan and Canada forecasted to grow 8% and 9%, respectively.
• Demand for PCR diagnostic technology to dominate the market over next ten years.

“Increasing awareness towards early detection of cancer using molecular diagnostics to nudge demand for oncology molecular diagnostics over coming years,” says a Fact.MR analyst.

Competitive Landscape

Top service providers of oncology molecular diagnostics, in an attempt to gain stability, are adopting strategies such as specialized product development. Leading market players in oncology molecular diagnostics are also entering into collaborations with top oncology molecular diagnostic instrument brands, for development of companion diagnostic pertaining to cancer.

Some of the key developments are:

• In September 2015; Roche launched the Cobas EGFR Mutation Test v2, which is used for diagnosis of Non-Small Cell Lung Cancer (NSCLC), which is expected to drive the growth of this market.
• Qiagen and Lilly announced their plans to co-develop companion diagnostics for targeting common cancer biomarkers.
• In February 2019, ICON plc, a US-based biotechnology company, acquired MolecularMD for an undisclosed amount. The acquisition enhances ICON’s laboratory offering in molecular diagnostic testing and brings to ICON expanded testing platforms, including next-generation sequencing, and immunohistochemistry (IHC).

Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=6864

Key Segments Covered in Oncology Molecular Diagnostic Industry Research

• By Product

  • Oncology Molecular Diagnostic Reagents & Kits
  • Oncology Molecular Diagnostic Instruments
    • Oncology Molecular Diagnostic Tabletop Instruments
    • Oncology Molecular Diagnostic Portable & PoC Instruments
  • Oncology Molecular Diagnostic Services & Software

• By Technology

  • Polymerase Chain Reaction (PCR) in Oncology Molecular Diagnostics
  • Isothermal Nucleic Acid Amplification Technology (INAAT) for Oncology Molecular Diagnostics
  • DNA Sequencing & Next-Generation Sequencing (NGS) for Oncology Molecular Diagnostics
  • In Situ Hybridization (ISH) Technology for Oncology Molecular Diagnostics
  • DNA Chips and Microarrays for Oncology Molecular Diagnostics

• By End User

  • Oncology Molecular Diagnostic Used in Diagnostic Laboratories
  • Oncology Molecular Diagnostic Used in Hospitals & Clinics

For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/6864

More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the oncology molecular diagnostic market, presenting historical market data (2016-2020) and forecast statistics for the period of 2021-2031.

The study reveals essential insights on the basis of product (reagents & kits and services & software) technology (polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization and DNA microarrays) end user (diagnostic laboratories and hospitals & clinics) across major regions of the world (North America, Europe, Asia Pacific, Central & South America, and the Middle East & Africa).

For More Insight- https://www.factmr.com/article/124/latest-trends-in-the-healthcare-industry-how-has-it-transformed-businesses

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com